RTI Surgical and Exactech Announce Strategic Partnership (PR Newswire)

RTI Surgical and Exactech Announce Strategic Partnership

UF startup and UF Innovate | Sid Martin Biotech alum RTI Surgical Holdings, Inc., a leading surgical implant company providing blue-chip OEM customers with a portfolio of tissue-based, synthetic and metal implants, has announced it has entered into a long-term strategic agreement with Gainesville-based and leading global medical device OEM Exactech, related to the development and supply of biologic bone substitutes.

As part of the agreement, RTI Surgical has acquired Exactech’s Optecure®, a 510(k)- cleared demineralized bone matrix for use as a bone graft extender in the spine, pelvis, and extremities. Optecure® will complement RTI Surgical’s market-leading portfolio of bone graft substitutes.

“Biologic materials that support joint replacement surgery are an important facet of Exactech’s business,” said Exactech CEO Darin Johnson. “This collaboration with RTI allows each company to focus on our unique strengths. RTI has specialized expertise in the procurement, processing and manufacturing of human-derived tissue-based implants and Exactech markets and distributes the clinical solutions to help surgeons treat patients. We are pleased that this deal strengthens our long-standing partnership and positions us to have a more stable supply to support our selling efforts.”

Learn more about RTI Surgical and Exactech Announce Strategic Partnership.